Prevalence and risk factors of hyperprolactinemia among patients with various psychiatric diagnoses and medications

References

• Ajmal, A., Joffe, H., & Nachtigall, L. B. (2014). Psychotropic-induced hyperprolactinemia: A clinical review. Psychosomatics, 55, 29–36. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/24140188
   PubMed Web of Science ®Google Scholar
• Arakawa, R., Okumura, M., Ito, H., Takano, A., Takahashi, H., Takano, H., … Suhara, T. (2010). Positron emission tomography measurement of dopamine D2 receptor occupancy in the pituitary and cerebral cortex: Relation to antipsychotic-induced hyperprolactinemia. The Journal of Clinical Psychiatry, 71, 1131–1137. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/20361897
   PubMed Web of Science ®Google Scholar
• Bushe, C., Shaw, M., & Peveler, R. C. (2008). A review of the association between antipsychotic use and hyperprolactinaemia. Journal of Psychopharmacology (Oxford, England), 22, 46–55. doi:10.1177/0269881107088435
   PubMedGoogle Scholar
• Haddad, P. M., & Wieck, A. (2004). Antipsychotic-induced hyperprolactinaemia: Mechanisms, clinical features and management. Drugs, 64, 2291–2314. doi:10.2165/00003495-200464200-00003
   PubMed Web of Science ®Google Scholar
• Halbreich, U., Kinon, B. J., Gilmore, J. A., & Kahn, L. S. (2003). Elevated prolactin levels in patients with schizophrenia: Mechanisms and related adverse effects. Psychoneuroendocrinology, 28 Suppl 1, 53–67. doi:10.1016/S0306-4530(02)00112-9
   PubMed Web of Science ®Google Scholar
• De Hert, M., Dobbelaere, M., Sheridan, E. M., Cohen, D., & Correll, C. U. (2011). Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice. European Psychiatry, 26, 144–158. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/21295450
   PubMed Web of Science ®Google Scholar
• Holt, R. I. (2008). Medical causes and consequences of hyperprolactinaemia. A context for psychiatrists. Journal of Psychopharmacology (Oxford, England), 22, 28–37. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/18477618
   PubMedGoogle Scholar
• Holt, R. I., & Peveler, R. C. (2011). Antipsychotics and hyperprolactinaemia: Mechanisms, consequences and management. Clinical Endocrinology, 74, 141–147. doi:10.1111/j.1365-2265.2010.03814.x
   PubMed Web of Science ®Google Scholar
• Hummer, M., & Huber, J. (2004). Hyperprolactinaemia and antipsychotic therapy in schizophrenia. Current Medical Research and Opinion, 20, 189–197. doi:10.1185/030079903125002865
   PubMed Web of Science ®Google Scholar
• Kikuchi, T., Iwamoto, K., Sasada, K., Aleksic, B., Yoshida, K., & Ozaki, N. (2012). Sexual dysfunction and hyperprolactinemia in Japanese schizophrenic patients taking antipsychotics. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 37, 26–32. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/22172534
   PubMed Web of Science ®Google Scholar
• Kinon, B. J., Gilmore, J. A., Liu, H., & Halbreich, U. M. (2003a). Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology, 28 Suppl 2, 55–68. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12650681
   PubMed Web of Science ®Google Scholar
• Kinon, B. J., Gilmore, J. A., Liu, H., & Halbreich, U. M. (2003b). Hyperprolactinemia in response to antipsychotic drugs: Characterization across comparative clinical trials. Psychoneuroendocrinology, 28, 69–82. doi:10.1016/S0306-4530(02)00128-2
   PubMed Web of Science ®Google Scholar
• Kohen, D., & Wildgust, H. J. (2008). The evolution of hyperprolactinaemia as an entity in psychiatric patients. Journal of Psychopharmacology, 22, 6–11. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/18477616
   PubMedGoogle Scholar
• Madhusoodanan, S., Parida, S., & Jimenez, C. (2010). Hyperprolactinemia associated with psychotropics – A review. Human Psychopharmacology, 25, 281–297. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/20521318
   PubMed Web of Science ®Google Scholar
• Meaney, A. M., Smith, S., Howes, O. D., O’Brien, M., Murray, R. M., & O’Keane, V. (2004). Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. British Journal of Psychiatry, 184, 503–508. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/15172944
   PubMed Web of Science ®Google Scholar
• Milano, W., Colletti, C., & Capasso, A. (2017). Hyperprolactinemia induced by antipsychotics: From diagnosis to treatment approach. Endocrine, Metab Immune Disord - Drug Targets [Internet], 17, 38–55. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/28440197
   PubMed Web of Science ®Google Scholar
• Misra, M., Papakostas, G. I., & Klibanski, A. (2004). Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. The Journal of Clinical Psychiatry, 65, 1607–1618, 1760–1761. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/15641865
   PubMed Web of Science ®Google Scholar
• Montejo, A. L. (2008). Prolactin awareness: An essential consideration for physical health in schizophrenia. European Neuropsychopharmacology, 18 Suppl 2, S108–S114. doi:10.1016/j.euroneuro.2008.02.004
   PubMed Web of Science ®Google Scholar
• Montgomery, J., Winterbottom, E., Jessani, M., Kohegyi, E., Fulmer, J., Seamonds, B., & Josiassen, R. C. (2004). Prevalence of hyperprolactinemia in schizophrenia: Association with typical and atypical antipsychotic treatment. Journal of Clinical Psychiatry, 65, 1491–1498. Retrieved from http://www.psychiatrist.com/JCP/article/Pages/2004/v65n11/v65n1108.aspx
   PubMed Web of Science ®Google Scholar
• O’Keane, V. (2008). Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia. Journal of Psychopharmacology, 22, 70–75. doi:10.1177/0269881107088439
   PubMedGoogle Scholar
• Peuskens, J., Pani, L., Detraux, J., & De Hert, M. (2014). The effects of novel and newly approved antipsychotics on serum prolactin levels: A comprehensive review. CNS Drugs, 28, 421–453. doi:10.1007/s40263-014-0157-3
   PubMed Web of Science ®Google Scholar
• Peveler, R. C., Branford, D., Citrome, L., Fitzgerald, P., Harvey, P. W., Holt, R. I., … O’Keane, V., et al. (2008). Antipsychotics and hyperprolactinaemia: Clinical recommendations. Journal of Psychopharmacology (Oxford, England), 22, 98–103. doi:10.1177/0269881107087346
   PubMedGoogle Scholar
• Pigato, G., Piazzon, G. V. M., Di Florio, A., Ermani, M., Toffanin, T., & Perini, G. I. (2015). Early hyperprolactinaemia in acute psychiatric inpatients: A cross-sectional study Iperprolattinemia precoce in pazienti ricoverati in sPdc: Uno studio trasversale. Journal of Psychopathology, 21, 226–230.
   Google Scholar
• Serri, O., Chik, C. L., Ur, E., & Ezzat, S. (2003). Diagnosis and management of hyperprolactinemia. CMAJ, 169, 575–581. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12975226
   PubMed Web of Science ®Google Scholar
• Smith, S., Wheeler, M. J., Murray, R., & O’Keane, V. (2002). The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis. Journal of Clinical Psychopharmacology, 22, 109–114. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/11910254
   PubMed Web of Science ®Google Scholar
• Vanderpump, M. P., French, J. M., Appleton, D., Tunbridge, W. M., & Kendall-Taylor, P. (1998). The prevalence of hyperprolactinaemia and association with markers of autoimmune thyroid disease in survivors of the Whickham Survey cohort. Clinical Endocrinology, 48, 39–44. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/9509066
   PubMed Web of Science ®Google Scholar
• Voicu, V., Medvedovici, A., Ranetti, A. E., & Rădulescu, F. Ş. (2013). Drug-induced hypo- and hyperprolactinemia: Mechanisms, clinical and therapeutic consequences. Expert Opinion on Drug Metabolism & Toxicology, 9, 955–968. Retrieved from http://www.tandfonline.com/doi/full/10.1517/17425255.2013.791283
   PubMed Web of Science ®Google Scholar
• Wong-Anuchit, C. (2016). Clinical management of antipsychotic-induced hyperprolactinemia. Perspectives in Psychiatric Care, 52, 145–152. doi:10.1111/ppc.12111
   PubMed Web of Science ®Google Scholar